Malvern-based pharmaceutical company Baudax Bio recently purchased TeraImmune, a biotechnology company focused on therapies for autoimmune diseases.
The combined company will advance the development of TeraImmune’s immune-cell therapies. The therapies use natural regulatory T cells (Tregs) isolated from patients and induced Tregs converted from a patient’s T-effector cells.
The technology is designed for conditions that suppress unwanted immune reactions and includes drugs for Atopic Dermatitis and Hemophilia A.
“This combination blends the world class scientific expertise of the TeraImmune team with the Baudax team’s proven ability to execute clinical development programs, which we believe is a win for the shareholders of both companies,” Gerri Henwood, Baudax president and CEO,
said. “This merger adds TeraImmune’s TI-168 asset to the Baudax portfolio—a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.”
Both companies’ board of directors unanimously approved the transaction.
TeraImmune outstanding equity interests were exchanged for a combination of Baudax common stock and shares of Series X Non-Voting Convertible Preferred Stock which will automatically convert into 1,000 shares of common stock. Conversion is pending shareholder approval and is subject to certain ownership limitations.
Dr. Yong Chan Kim, former TeraImmune CEO, will be appointed to the Baudax board of directors.